Craig Tooman
Chief Executive Officer at SILENCE THERAPEUTICS PLC
Net worth: 63 428 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ingmar Hoerr | M | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 21 years |
| Carolyn Cross | F | 62 | 28 years | |
| Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 years |
| Jean Charest | M | 65 | 6 years | |
| Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 years |
| Nicolas Loebel | M | 64 | 20 years | |
| Tom Dawson | M | - | - | |
| Baron Jean Stéphenne | M | 73 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Simon Sinclair | M | 52 | 3 years | |
| Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 years |
| Rhonda L. Hellums | F | 52 | 8 years | |
| Steven Romano | M | 64 | 5 years | |
| Friedrich von Bohlen und Halbach | M | 60 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
| Gem Hopkins | M | - | 4 years | |
| Marie Wikström Lindholm | M | - | 7 years | |
| Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 years |
| Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 years |
| Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
| Roger Andersen | M | - | - | |
| Angelika Vance | F | - | - | |
| Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 6 years |
| Sarah Fakih | M | - | - | |
| Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 years |
| David Lemus | M | 61 | 6 years | |
| Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Junaid Bajwa | M | 45 | 3 years | |
| Ralf Clemens | M | 71 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Mike Farrar | M | 64 | 3 years | |
| Jean Duvall | F | 63 | 3 years | |
| Hans Tanner | M | 72 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
| Pierre Kemula | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 years |
| Jason Hickok | M | - | - | |
| J.P. Gabriel | M | - | 1 years | |
| Patrick Baumhof | M | - | - | |
| Klaus Schollmeier | M | 67 | 2 years | |
| Bettina Jödicke-Braas | F | - | - | |
| Bill Kanz | M | - | - | |
| Myriam Mendila | M | 58 | 1 years | |
| Iain Ross | M | 71 | 5 years | |
| Viola Bronsema | M | 61 | 4 years | |
| Nikita Parkhaev | F | - | - | |
| James Ede-Golightly | M | 44 | 5 years | |
| Malte Greune | M | 59 | 3 years | |
| Antony Blanc | M | 57 | 4 years | |
| Eric Fink | M | - | 2 years | |
| Jean Stephenne | M | 75 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
| Michael Davidson | M | 67 | 3 years | |
| Linnea Corwin Elrington | F | - | 7 years | |
| Alexander Zehnder | M | 54 | 1 years | |
| Eric Floyd | M | 62 | 5 years | |
| Curtis Rambaran | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew D. Rackear | M | 70 | 11 years | |
| Mark Rothera | M | 61 | 2 years | |
| Jeffrey H. Buchalter | M | 67 |
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 9 years |
| Kenneth Zuerblis | M | 64 | 14 years | |
| Richard L. Love | M | 81 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 10 years |
| Robert O’Holla | M | 72 | 7 years | |
| Thomas F. Deuel | M | 89 | 3 years | |
| Richard Young | M | 70 | 3 years | |
| Evan S. Melrose | M | 54 | 3 years | |
| Alistair Gray | M | 75 | 9 years | |
| Alexander Denner | M | 54 | 4 years | |
| Giles Campion | M | 69 | 4 years | |
| Bob C. Salisbury | M | 80 | 8 years | |
| Timothy Patrick Lynch | M | 54 | 3 years | |
| Brian Levy | M | 72 | 4 years | |
| Robert Quinn | M | 41 | 4 years | |
| Tim McInerney | M | 63 | 7 years | |
| Anthony J. Yost | M | 65 | 7 years | |
| Aby Buchbinder | M | 55 | 7 years | |
| Lee M. Greenberger | M | - | - | |
| Klaus Edvardsen | M | 62 | 1 years | |
| Javesh Shah | M | - | - | |
| Sunil Mehta | M | 65 | - | |
| Shauna M. Tholen | F | - | 1 years | |
| Larry Miller | M | - | 1 years | |
| John Strafford | M | - | 5 years | |
| John D. Weinberg | M | 57 | 2 years | |
| Jorgen Wittendorff | M | - | 4 years | |
| Kalyanasundaram Sundaram | M | 70 | - | |
| Dimitris Voliotis | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 years |
| Joseph Errico | M | 55 | - | |
| Richard Mulligan | M | 69 | 4 years | |
| Franz-Werner Haas | M | 54 | 11 years | |
| Joy Amundson | F | 69 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 2 years |
| Bruce Williams | M | 69 | 2 years | |
| Ulrich Grau | M | 75 | 3 years | |
| Mark P. Mellin | M | 62 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 4 years |
| Victor Micati | M | 83 | 6 years | |
| Martin D. Meglasson | M | 74 | 4 years | |
| Eric J. Liebler | M | 60 | 3 years | |
| Gregory Weaver | M | 68 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 3 years |
| Jack Geltosky | M | 78 | 1 years | |
| Ivan D. Horak | M | 73 | 6 years | |
| Phillip M. Renfro | M | 78 | 5 years | |
| Göran Albert Ando | M | 75 | - | |
| Rosina B. Dixon | M | 81 | 12 years | |
| Corey Levenson | M | 69 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 8 years |
| Daniel L. Menichella | M | 64 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 years |
| Mike Long | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 38 | 38.00% |
| Germany | 29 | 29.00% |
| United Kingdom | 19 | 19.00% |
| Canada | 15 | 15.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Craig Tooman
- Personal Network